These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 33199386)

  • 41. A Review of Moxifloxacin for the Treatment of Drug-Susceptible Tuberculosis.
    Naidoo A; Naidoo K; McIlleron H; Essack S; Padayatchi N
    J Clin Pharmacol; 2017 Nov; 57(11):1369-1386. PubMed ID: 28741299
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Moxifloxacin Replacement in Contemporary Tuberculosis Drug Regimens Is Ineffective against Persistent Mycobacterium tuberculosis in the Cornell Mouse Model.
    Liu Y; Pertinez H; Davies GR; Gillespie SH; Coates AR; Hu Y
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29661869
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Output-driven feedback system control platform optimizes combinatorial therapy of tuberculosis using a macrophage cell culture model.
    Silva A; Lee BY; Clemens DL; Kee T; Ding X; Ho CM; Horwitz MA
    Proc Natl Acad Sci U S A; 2016 Apr; 113(15):E2172-9. PubMed ID: 27035987
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling.
    Gumbo T; Louie A; Deziel MR; Parsons LM; Salfinger M; Drusano GL
    J Infect Dis; 2004 Nov; 190(9):1642-51. PubMed ID: 15478070
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time.
    Lee BY; Clemens DL; Silva A; Dillon BJ; Masleša-Galić S; Nava S; Ding X; Ho CM; Horwitz MA
    Nat Commun; 2017 Jan; 8():14183. PubMed ID: 28117835
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Recent updates on drug resistance in Mycobacterium tuberculosis.
    Singh R; Dwivedi SP; Gaharwar US; Meena R; Rajamani P; Prasad T
    J Appl Microbiol; 2020 Jun; 128(6):1547-1567. PubMed ID: 31595643
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A Novel Small-Molecule Inhibitor of the
    Sukheja P; Kumar P; Mittal N; Li SG; Singleton E; Russo R; Perryman AL; Shrestha R; Awasthi D; Husain S; Soteropoulos P; Brukh R; Connell N; Freundlich JS; Alland D
    mBio; 2017 Feb; 8(1):. PubMed ID: 28196957
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Perspectives on tuberculosis pathogenesis and discovery of anti- tubercular drugs.
    Ntie-Kang F; Yong JN; Owono Owono LC; Sippl W; Megnassan E
    Curr Med Chem; 2014; 21(30):3466-77. PubMed ID: 25005178
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
    Doan TN; Cao P; Emeto TI; McCaw JM; McBryde ES
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249697
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Design of high-order antibiotic combinations against M. tuberculosis by ranking and exclusion.
    Yilancioglu K; Cokol M
    Sci Rep; 2019 Aug; 9(1):11876. PubMed ID: 31417151
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Optimized Background Regimen for Treatment of Active Tuberculosis with the Next-Generation Benzothiazinone Macozinone (PBTZ169).
    Lupien A; Vocat A; Foo CS; Blattes E; Gillon JY; Makarov V; Cole ST
    Antimicrob Agents Chemother; 2018 Nov; 62(11):. PubMed ID: 30126954
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dosing regimens in the treatment of tuberculosis.
    Blom-Bülow B
    Scand J Infect Dis Suppl; 1990; 74():258-61. PubMed ID: 2129066
    [TBL] [Abstract][Full Text] [Related]  

  • 53. An overview of new antitubercular drugs, drug candidates, and their targets.
    Bahuguna A; Rawat DS
    Med Res Rev; 2020 Jan; 40(1):263-292. PubMed ID: 31254295
    [TBL] [Abstract][Full Text] [Related]  

  • 54. SILA-421 activity in vitro against rifampicin-susceptible and rifampicin-resistant Mycobacterium tuberculosis, and in vivo in a murine tuberculosis model.
    de Knegt GJ; Bakker-Woudenberg IA; van Soolingen D; Aarnoutse R; Boeree MJ; de Steenwinkel JE
    Int J Antimicrob Agents; 2015 Jul; 46(1):66-72. PubMed ID: 25951996
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The future for early-stage tuberculosis drug discovery.
    Zuniga ES; Early J; Parish T
    Future Microbiol; 2015; 10(2):217-29. PubMed ID: 25689534
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Tuberculosis: clinical trials and new drug regimens.
    Kwon YS; Jeong BH; Koh WJ
    Curr Opin Pulm Med; 2014 May; 20(3):280-6. PubMed ID: 24614239
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Activity of moxifloxacin and linezolid against Mycobacterium tuberculosis in combination with potentiator drugs verapamil, timcodar, colistin and SQ109.
    de Knegt GJ; van der Meijden A; de Vogel CP; Aarnoutse RE; de Steenwinkel JE
    Int J Antimicrob Agents; 2017 Mar; 49(3):302-307. PubMed ID: 28162983
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Developing New Drugs for Mycobacterium tuberculosis Therapy: What Information Do We Get from Preclinical Animal Models?
    Drusano GL; Duncanson B; Scanga CA; Kim S; Schmidt S; Neely MN; Yamada WM; Vicchiarelli M; Peloquin CA; Louie A
    Antimicrob Agents Chemother; 2020 Nov; 64(12):. PubMed ID: 32958720
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Tools to develop antibiotic combinations that target drug tolerance in
    Greenstein T; Aldridge BB
    Front Cell Infect Microbiol; 2022; 12():1085946. PubMed ID: 36733851
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis.
    ; Ahmad N; Ahuja SD; Akkerman OW; Alffenaar JC; Anderson LF; Baghaei P; Bang D; Barry PM; Bastos ML; Behera D; Benedetti A; Bisson GP; Boeree MJ; Bonnet M; Brode SK; Brust JCM; Cai Y; Caumes E; Cegielski JP; Centis R; Chan PC; Chan ED; Chang KC; Charles M; Cirule A; Dalcolmo MP; D'Ambrosio L; de Vries G; Dheda K; Esmail A; Flood J; Fox GJ; Fréchet-Jachym M; Fregona G; Gayoso R; Gegia M; Gler MT; Gu S; Guglielmetti L; Holtz TH; Hughes J; Isaakidis P; Jarlsberg L; Kempker RR; Keshavjee S; Khan FA; Kipiani M; Koenig SP; Koh WJ; Kritski A; Kuksa L; Kvasnovsky CL; Kwak N; Lan Z; Lange C; Laniado-Laborín R; Lee M; Leimane V; Leung CC; Leung EC; Li PZ; Lowenthal P; Maciel EL; Marks SM; Mase S; Mbuagbaw L; Migliori GB; Milanov V; Miller AC; Mitnick CD; Modongo C; Mohr E; Monedero I; Nahid P; Ndjeka N; O'Donnell MR; Padayatchi N; Palmero D; Pape JW; Podewils LJ; Reynolds I; Riekstina V; Robert J; Rodriguez M; Seaworth B; Seung KJ; Schnippel K; Shim TS; Singla R; Smith SE; Sotgiu G; Sukhbaatar G; Tabarsi P; Tiberi S; Trajman A; Trieu L; Udwadia ZF; van der Werf TS; Veziris N; Viiklepp P; Vilbrun SC; Walsh K; Westenhouse J; Yew WW; Yim JJ; Zetola NM; Zignol M; Menzies D
    Lancet; 2018 Sep; 392(10150):821-834. PubMed ID: 30215381
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.